Beta Drugs Ltd (NSE: BETA) is a Panchkula, Haryana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,897 Cr, it ranks #1,272 by market cap among the 6,197 Indian listed companies on FinBizNet, and #39 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,811.20 (as of 16 Nov 2026), the share price is 35.5% below its 52-week high of ₹2,807.90 and 82.9% above its 52-week low of ₹990.10. The share price is up 8.8% over one year and down 30.0% over three months.
| Current Price | ₹1,811.20 |
|---|---|
| Market Cap | ₹1,897 Cr |
| NSE Symbol | BETA |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 44.9 |
| Return on Equity | 18.77% |
| Return on Assets | 7.85% |
| 52-Week Range | ₹990.10 – ₹2,807.90 |
| 1-Year Price Change | +8.8% |
| 3-Month Price Change | -30.0% |
| Beta (1Y) | 0.1 |
| Headquarters | Panchkula, Haryana |
| Website | betadrugslimited.com |
| Revenue | ₹137 Cr |
|---|---|
| Net Profit | ₹19 Cr |
| Net Margin | 14.0% |
| EPS (Basic) | ₹16.59 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Beta Drugs Ltd reported revenue of ₹137 Cr in Q2 FY27, up 9.5% from ₹126 Cr in Q1 FY27. It posted a net profit of ₹19 Cr for the quarter, against a net profit of ₹16 Cr in Q1 FY27 (up 16.9%). Across the 4 quarters from Q3 FY26 to Q2 FY27, quarterly revenue ranged from ₹87 Cr (Q3 FY26) to ₹137 Cr (Q2 FY27). The company was profitable in each of these 4 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹137 Cr | ₹19 Cr | 14.0% |
| Q1 FY27 | ₹126 Cr | ₹16 Cr | 13.1% |
| Q4 FY26 | ₹94 Cr | ₹9 Cr | 9.6% |
| Q3 FY26 | ₹87 Cr | ₹9 Cr | 9.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 58.91% of Beta Drugs Ltd's shares as of Sept 2026, against 64.90% in Dec 2025 (−5.99 percentage points). Delivery averaged 44.6% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.
1. Manufacturing of Oncology Medicines-This segment develops, manufactures, and trades in oncology medicines.
1. Trading and Manufacturing of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Beta Drugs Ltd | ₹1,897 Cr | 44.9 | 18.77% | ₹137 Cr | +8.8% |
Listed by market capitalisation. Ratios are shown for context only.
Beta Drugs Ltd is trading at ₹1,811.20, with a market capitalisation of ₹1,897 Cr.
Beta Drugs Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Beta Drugs Ltd has a P/E of 44.9 and a return on equity of 18.77%.
Beta Drugs Ltd is listed on the NSE under the symbol BETA.
Beta Drugs Ltd's share price is up 8.8% over one year and down 30.0% over three months. Its 52-week range is ₹990.10 to ₹2,807.90.
In Q2 FY27, Beta Drugs Ltd reported revenue of ₹137 Cr and net profit of ₹19 Cr, with basic EPS of ₹16.59 (consolidated, parsed from the company's exchange filing).
Promoters held 58.91% of Beta Drugs Ltd's shares as of Sept 2026, against 64.90% in Dec 2025 (−5.99 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.